請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16129
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳進庭(Chin-Tin Chen) | |
dc.contributor.author | Che-Hao Wang | en |
dc.contributor.author | 王哲豪 | zh_TW |
dc.date.accessioned | 2021-06-07T18:02:09Z | - |
dc.date.copyright | 2012-08-07 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-03 | |
dc.identifier.citation | 1. Korf, B.R., Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis. Curr Opin Neurol, 1997. 10(2): p. 131-6.
2. Rose, V.M., Neurocutaneous syndromes. Mo Med, 2004. 101(2): p. 112-6. 3. U, A., Monstrorum Historia cum Paralipomenis Historiae Omnium Animalium. Typis Nicolai Tibaldini: Bononiae, 1642. 4. Smith, R.W., A treatise on the pathology, diagnosis and treatment of neuroma. 1849. Clin Orthop Relat Res, 1989(245): p. 3-9. 5. FULTON, J.F., Robert W. Smith's Description of Generalized Neurofibromatosis (1849). New England Journal of Medicine, 1929. 200(26): p. 1315-1317. 6. FD, V.R., Under die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Hirschwald, 1882. 7. Crowe, F.W., A clinical, pathological, and genetic study of multiple neurofibromatosis. American lecture series, publication no 281 The Bannerstone Division of American lectures in dermatology1956, Springfield, Ill.,: Thomas. 181 p. 8. Cawthon, R.M., et al., A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell, 1990. 62(1): p. 193-201. 9. Wallace, M.R., et al., Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science, 1990. 249(4965): p. 181-6. 10. Li, Y., et al., Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics, 1995. 25(1): p. 9-18. 11. von Deimling, A., W. Krone, and A.G. Menon, Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol, 1995. 5(2): p. 153-62. 12. Daston, M.M., et al., The Protein Product of the Neurofibromatosis Type-1 Gene Is Expressed at Highest Abundance in Neurons, Schwann-Cells, and Oligodendrocytes. Neuron, 1992. 8(3): p. 415-428. 13. Riccardi, V.M. and J. Smirniotopoulos, Neurofibromatosis, Phenotype, Natural History, and Pathogenesis. Journal of Neuropathology & Experimental Neurology, 1992. 51(6): p. 658. 14. Carey, J.C., J.M. Laub, and B.D. Hall, Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Artic Ser, 1979. 15(5B): p. 271-81. 15. DeClue, J.E., B.D. Cohen, and D.R. Lowy, Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci U S A, 1991. 88(22): p. 9914-8. 16. Yunoue, S., et al., Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem, 2003. 278(29): p. 26958-69. 17. Xu, G.F., et al., The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell, 1990. 63(4): p. 835-41. 18. DeClue, J.E., et al., Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest, 2000. 105(9): p. 1233-41. 19. Wu, J., et al., Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell, 2008. 13(2): p. 105-16. 20. DeBella, K., J. Szudek, and J.M. Friedman, Use of the National Institutes of Health Criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics, 2000. 105(3): p. 608-614. 21. Huson, S.M., P.S. Harper, and D.A. Compston, Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain, 1988. 111 ( Pt 6): p. 1355-81. 22. OD, W. and R. H, Pathology of neurofibromatosis 1 and 2. In: Huson SM, Hughes RAC, eds. The Neurofibromatoses. London: Chapman and Hall, 1994: p. 135-9. 23. Scheithauer, et al., Tumors of the Peripheral Nervous System. Washington, DC: Armed Forces Institute of Pathology, 1999. 24. Kloos, R.T., et al., Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med, 1996. 37(11): p. 1778-83. 25. Listernick, R., et al., Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol, 1997. 41(2): p. 143-9. 26. Huson, S., D. Jones, and L. Beck, Ophthalmic manifestations of neurofibromatosis. Br J Ophthalmol, 1987. 71(3): p. 235-8. 27. Korf, B.R., Clinical features and pathobiology of neurofibromatosis 1. J Child Neurol, 2002. 17(8): p. 573-7; discussion 602-4, 646-51. 28. Elefteriou, F., et al., Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A, 2009. 149A(10): p. 2327-38. 29. Loh, K.C., et al., Phaeochromocytoma: a ten-year survey. QJM, 1997. 90(1): p. 51-60. 30. A, K., C. J, and C. J, Periampullary neoplasms in von Recklinghausen's disease. Surgery, 1989. 106: p. 815-9. 31. Ilgren, E.B., L.M. Kinnier-Wilson, and C.A. Stiller, Gliomas in neurofibromatosis: a series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytomas. Pathol Annu, 1985. 20 Pt 1: p. 331-58. 32. Bollag, G., et al., Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells (vol 12, pg 144, 1996). Nature Genetics, 1996. 12(4): p. 458-458. 33. Cnossen, M.H., et al., Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics, 1997. 100(4): p. 667-70. 34. Adams, C., W.A. Fletcher, and S.T. Myles, Chiasmal glioma in neurofibromatosis type 1 with severe visual loss regained with radiation. Pediatr Neurol, 1997. 17(1): p. 80-2. 35. 洪士軒, 五氨基酮戊酸光動力治療用於第一型神經纖維瘤病之研究探討. 國立台灣大學生化科技系研究所碩士論文, 2011. 36. Miller, S.J., et al., Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Research, 2006. 66(5): p. 2584-91. 37. S, R., Y. Q, and F. J, Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet, 2001. 68: p. 1110-1118. 38. Friedman, J.M., et al., Neurofibromatosis: phenotype, natural history, and pathogenesis. Baltimore (MD) 3rd ed. : Johns Hopkins University Press, 1999. 39. Wong, W.W., et al., Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys, 1998. 42(2): p. 351-60. 40. Rosenbaum, T., K.M. Patrie, and N. Ratner, Neurofibromatosis type 1: Genetic and cellular mechanisms of peripheral nerve tumor formation. Neuroscientist, 1997. 3(6): p. 412-420. 41. Morioka, N., et al., A case of neurofibrosarcoma associated with neurofibromatosis: light microscopic, ultrastructural, immunohistochemical and biochemical investigations. J Dermatol, 1990. 17(5): p. 312-6. 42. Ferner, R.E. and D.H. Gutmann, International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Research, 2002. 62(5): p. 1573-7. 43. Fishbein, L., et al., Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet, 2005. 157(2): p. 181-6. 44. Menon, A.G., et al., Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A, 1990. 87(14): p. 5435-9. 45. Nielsen, G.P., et al., Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. American Journal of Pathology, 1999. 155(6): p. 1879-1884. 46. Holtkamp, N., et al., EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol, 2008. 10(6): p. 946-57. 47. Sheela, S., V.M. Riccardi, and N. Ratner, Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol, 1990. 111(2): p. 645-53. 48. Ferner, R.E., et al., Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 2007. 44(2): p. 81-8. 49. Ducatman, B.S., et al., Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer, 1986. 57(10): p. 2006-21. 50. Widemann, B.C., et al., Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol, 2006. 24(3): p. 507-16. 51. Gupta, A., et al., Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology, 2003. 60(1): p. 130-132. 52. Riccardi, V.M., A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol, 1993. 129(5): p. 577-81. 53. Riccardi, V.M., Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen. Arch Dermatol, 1987. 123(8): p. 1011-6. 54. H, D., T. J, and B. W, Photodynamic Therapy. Journal of the National Cance Institute, 1998. 12(90): p. 889-905. 55. Henderson, B.W., et al., Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Research, 1985. 45(2): p. 572-6. 56. Daniell, M.D. and J.S. Hill, A History of Photodynamic Therapy. Australian and New Zealand Journal of Surgery, 1991. 61(5): p. 340-348. 57. N, F., Phototherapy. Edward Amold, 1901. 58. O, R., Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Zeitung Biol, 1900(39): p. p.524-526. 59. Tappeiner, V. and A. Jesionek, Therapeutische versuche mit fluoreszierenden stoffen. Muench Med Wochenschr, 1903(47): p. p.2042-2044. 60. Hausmann, W., Die sensiblisierende Wirkung des Hematoporphyrins. . Biochem Zeitung, 1911(30): p. p. 276-316. 61. Lipson, R.L. and E.J. Baldes, The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol, 1960. 82: p. 508-16. 62. Diamond, I., Photodynamic therapy of malignant tumours. . The Lancet, 1972(300): p. p. 1175-1177. 63. Dougherty, T.J., et al., Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst, 1975. 55(1): p. 115-21. 64. Kelly, J.F. and M.E. Snell, Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol, 1976. 115(2): p. 150-1. 65. Kelly, J.F., M.E. Snell, and M.C. Berenbaum, Photodynamic Destruction of Human Bladder Carcinoma. British Journal of Cancer, 1975. 31(2): p. 237-244. 66. Dougherty, T.J., et al., Photoradiation therapy for the treatment of malignant tumors. Cancer Research, 1978. 38(8): p. 2628-35. 67. Henderson, B.W. and T.J. Dougherty, How Does Photodynimic Therapy Work? . Photochemistry and Photobiology, 1992. . 1(55): p. p 145-157. 68. Sharman, W.M., C.M. Allen, and J.E. van Lier, Photodynamic therapeutics: basic principles and clinical applications. Drug Discovery Today, 1999. 4(11): p. 507-517. 69. Dolmans, et al., Photodynamic therapy for cancer. Nat Rev Cancer, 2003. 5(3): p. p. 380-7. 70. Moan, J. and K. Berg, The Photodegradation of Porphyrins in Cells Can Be Used to Estimate the Lifetime of Singlet Oxygen. Photochemistry and Photobiology, 1991. 53(4): p. 549-553. 71. Foote, C.S., Definition of Type-I and Type-Ii Photosensitized Oxidation. Photochemistry and Photobiology, 1991. 54(5): p. 659-659. 72. Betz, M. and F., Untersuchungen uber die biologische photodynamische Wirkung des Hematoporphyrins und anderer Derivative des Blut und Galenafarbstoffs. . Dtsch Arch Klin, 1913(112): p. p. 476-503. 73. Policard, A., Etudes sur les aspects offerts par des tumeurs experimentales examinees a la lumiere de Wood. . Compt Rend Soc Biol, 1924.(91): p. p. 1432. 74. Schwartz, et al., Some relationships of porphyrins, X-rays and tumors. . Univ Minn Med Bull, 1955(27): p. p. 7-8. 75. Lipson, R.L., E.J. Baldes, and A.M. Olsen, Hematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J Thorac Cardiovasc Surg, 1961. 42: p. 623-9. 76. Inc, Q.P., Canadian health protection branch approves Photofrin for treatment of esophageal cancer. Press Release, 1995. 77. Berenbaum, M.C., R. Bonnett, and P.A. Scourides, In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer, 1982. 45(4): p. 571-81. 78. Berenbaum, M.C., G.W. Hall, and A.D. Hoyes, Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer, 1986. 53(1): p. 81-9. 79. Wan, S. and e. al., Transmittance of non-ionizing radiation in human tissue. Photochemistry and Photobiology.. 1981. 6 (34): p. p. 679-681. 80. Detty, M.R., S.L. Gibson, and S.J. Wagner, Current clinical and preclinical photosensitizers for use in photodynamic therapy. Journal of Medicinal Chemistry, 2004. 47(16): p. 3897-3915. 81. DrugBank., Aminolevulinic acid. http://www.drugbank.ca/drugs/DB00855. 82. Peng, Q., et al., 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol, 1997. 65(2): p. 235-51. 83. Novo, M., G.H. tmann, and H. Diddens, Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. Journal of Photochemistry and Photobiology. B: Biology, 1996. 2-3(34): p. p. 143-148. 84. Elfsson, B., et al., Stability of 5-aminolevulinic acid in aqueous solution. European Journal of Pharmaceutical Sciences, 1999. 7(2): p. 87-91. 85. Shemin, D. and C.S. Russell, Sigma-Aminolevulinic Acid, Its Role in the Biosynthesis of Porphyrins and Purines. Journal of the American Chemical Society, 1953. 75(19): p. 4873-4874. 86. Phillips, J.D. and J.P. Kushner, The heme biosynthesis pathway and clinical manifestations of abnormal function. Curr Protoc Toxicol, 2001. Chapter 8: p. Unit 8 1. 87. Yamamoto, M., et al., Structure, turnover, and heme-mediated suppression of the level of mRNA encoding rat liver delta-aminolevulinate synthase. J Biol Chem, 1988. 263(31): p. 15973-9. 88. Lang, K., et al., Aminolevulinic acid: pharmacological profile and clinical indication. Expert Opin Investig Drugs, 2001. 10(6): p. 1139-56. 89. Gibson, S.L., et al., Relationship of delta-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro. Biochem Biophys Res Commun, 1999. 265(2): p. 315-21. 90. Heyerdahl, H., et al., Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett, 1997. 112(2): p. 225-31. 91. McGivan, J.D., Rat hepatoma cells express novel transport systems for glutamine and glutamate in addition to those present in normal rat hepatocytes. Biochemical Journal, 1998. 330: p. 255-260. 92. Hilf, et al., Effect of 5-AmJnolevulinic Acid on Protoporphyrin IX Accumulation in Tumor Cells Transfected with Plasmids Containing Porphobilinogen Deaminase DNA. Photochemistry and Photobiology, 1999. 3(70): p. p. 334-340. 93. Van Hillegersberg, R., et al., Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology, 1992. 103(2): p. 647-51. 94. Morton, C.A., et al., Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol, 2002. 146(4): p. 552-67. 95. Berroeta, L., et al., A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol, 2007. 157(2): p. 401-3. 96. Warloe, T. and e. al., Photodynamic therapy with 5-aminoolevulinic acid-induced porphyrins and DMSO/E DTA for basal cell carcinoma. . Proc SPIE, 1995(2371): p. p. 226-235. 97. Pierre, M.B.R., et al., Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy. Pharmaceutical Research, 2006. 23(2): p. 360-366. 98. Goff, B.A., et al., Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs. J Photochem Photobiol B, 1992. 15(3): p. 239-51. 99. Gaullier, J.M., et al., Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Research, 1997. 57(8): p. 1481-1486. 100. Uehlinger, P., et al., 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B, 2000. 54(1): p. 72-80. 101. Chang, S.F., et al., Enhancement of 5-aminolevulinic acid-induced photodynamic therapy by a bioadhesive polymer. Journal of Dental Sciences, 2010. 5(1): p. 30-35. 102. Berg, K., et al., The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer, 1996. 74(5): p. 688-97. 103. Blake, E. and A. Curnow, The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX-induced PDT of Cultured Human Glioma Cells. Photochemistry and Photobiology, 2010. 86(5): p. 1154-1160. 104. Ohgari, Y. and e. al., Quinolone compounds enhance G-aminolevulinic acid-induced accumulation of protoporphyrin IX and photosensitivity of tumour cells. . Journal of Biochemistry, 2011. . 2)(149): p. p. 153-160. 105. Anand, S., et al., Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res, 2009. 15(10): p. 3333-43. 106. Sinha, A.K., et al., Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. British Journal of Cancer, 2006. 95(4): p. 485-495. 107. Bangham, A.D., M.M. Standish, and J.C. Watkins, Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 1965. 13(1): p. 238-52. 108. AD, B. and H. EW., Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. . J. Mol. Biol. , 1964. . 8: p. 660-668. 109. G, S. and W. G., Phospholipid spherules (liposome) as a model for biological membrance. J. Lipid Res., 1968. . 9: p. 310-318. 110. Gregoria.G and B.E. Ryman, Liposomes as Carriers of Enzymes or Drugs - New Approach to Treatment of Storage Diseases. Biochemical Journal, 1971. 124(5): p. P58-&. 111. TM, A. and C.L. . Serum-induced leakage of liposomes contents. Biochim. Biophys. Acta, 1980(597): p. 418-426. 112. GA, K., K. JA., and S. GL, .Interference of macrophages with immunotargeting of liposome. . J. Liposome Res., 2002. 12: p. 107-119. 113. Allen, T.M., Long-Circulating (Sterically Stabilized) Liposomes for Targeted Drug-Delivery. Trends in Pharmacological Sciences, 1994. 15(7): p. 215-220. 114. I, A., Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposome can eradicate lung cancer in mice. Cancer Research, 1993(53): p. 1484-1488. 115. Ostro, M.J. and P.R. Cullis, Use of Liposomes as Injectable-Drug Delivery Systems. American Journal of Hospital Pharmacy, 1989. 46(8): p. 1576-1587. 116. Cole, M.P., I.D. Todd, and P.M. Wilkinson, A preliminary trial of doxorubicin in advanced breast cancer and other malignant disease. Br J Cancer, 1974. 29(2): p. 114-6. 117. Schiller, J.H., Current standards of care in small-cell and non-small-cell lung cancer. Oncology, 2001. 61: p. 3-13. 118. D, C., et al., Breast cancer in the elderly. J Clin Oncol. , 2007. 14(25): p. 1882-1890. 119. Kelland, L.R., Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs, 2005. 10(2): p. 413-24. 120. G, T. and F. H., Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis., 2007. 5(49): p. 330-352. 121. AL, F., M. LS, and M. BB., Anthracycline-induced cardiotoxicit 1. Cardiovasc Hematol Agents Med Chem. , 2008. . 6((4)): p. 278-28. 122. Hong, R.L., et al., Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clinical Cancer Research, 1999. 5(11): p. 3645-3652. 123. Thompson, D.H., et al., Triggerable plasmalogen liposomes: improvement of system efficiency. Biochim Biophys Acta, 1996. 1279(1): p. 25-34. 124. Tseng, Y.L., J.J. Liu, and R.L. Hong, Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and TAT: A kinetic and efficacy study. Molecular Pharmacology, 2002. 62(4): p. 864-872. 125. Bondurant, B., A. Mueller, and D.F. O'Brien, Photoinitiated destabilization of sterically stabilized liposomes. Biochimica Et Biophysica Acta-Biomembranes, 2001. 1511(1): p. 113-122. 126. Eckert, J.M., et al., Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. Glia, 2009. 57(14): p. 1501-20. 127. Eckert, J.M., et al., Neuregulin-1b and Neuregulin-1a Differentially Affect the Migration and Invasion of Malignant Peripheral Nerve Sheath Tumor Cells. . GLIA 2009. 57: p. 1501-1520. 128. Holtkamp, N., et al., Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis, 2006. 27(3): p. 664-71. 129. Holtkamp, N., et al., Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 2004. 107(2): p. 159-68. 130. HP, K., et al., Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. . Am J Pathol. , 1999(155): p. 1855-1860. 131. Ling, B.C., et al., Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell, 2005. 7(1): p. 65-75. 132. Foley, K.M., et al., Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol, 1980. 7(4): p. 311-8. 133. Gabizon, A.A., Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Research, 1992. 52(4): p. 891-6. 134. Gabizon, A. and D. Papahadjopoulos, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6949-53. 135. Parr, M.J., et al., Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther, 1997. 280(3): p. 1319-27. 136. B, P., et al., Preclinical evaluation of a novel water-soluble chlorin E6 derivative (BLC 1010) as photosensitizer for the closure of the neovessels. . Photochem Photobiol., 2005. Nov-Dec 81((6):): p. 1505-10. 137. 彭柏鈞, 以C26腫瘤模式探討雙效型微脂體之最適治療條件。. 國立台灣大學微生物與生化科學研究所論文。, 2010. 138. 蔡宜珍, 雙效型微脂體用於抑制腫瘤生長之探討。. 國立台灣大學微生物與生化科學研究所碩士論文。, 2009. 139. Huang, S.K., et al., Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Research, 1992. 52(24): p. 6774-81. 140. Webber, J., et al., Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor. Journal of Photochemistry and Photobiology B-Biology, 2005. 78(2): p. 135-140. 141. Snyder, J.W., et al., Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Research, 2003. 63(23): p. 8126-31. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16129 | - |
dc.description.abstract | 惡性神經纖維鞘瘤 (Malignant peripheral nerve sheath tumor cell,MPNST) 為源自周邊神經細胞的腫瘤,主要病徵為病患表皮上會增生許多大小不一的神經纖維瘤 (neurofibroma) ,且腫瘤細胞容易轉移到身體其他部位。腫瘤除了會造成生理上的病痛之外,外觀上的不雅也嚴重影響患者的心理發展。MPNST細胞主要會沿著神經脈絡生長並與正常細胞緊密交纏,導致以外科手術切除腫瘤的困難度增高,且其對化療及放射線治療具有抗性,使得治療效果不佳。因此,本研究的目的為找尋更有效率治療MPNST的方法,希望將來能在臨床治療上提供幫助。在目前的臨床研究上,五氨基酮戊酸光動力療法 (5-Aminolevulinic acid photodynamic therapy, ALA-PDT) 因具有光感物質選擇性的累積於腫瘤之特質,藉由局部照光所產生的單態氧及自由基可專一地對腫瘤細胞造成破壞,因此本研究針對MPNST細胞進行光照治療處理。結果顯示,ALA-PDT可有效的毒殺MPNST細胞,且處理後存活下來之細胞的轉移能力顯著下降。另有文獻指出,Neurofibromin type1 (NF1) 基因的缺失容易導致良性的周邊神經瘤惡化,此外NF1基因缺失的MPNST細胞也被認為是較惡性的腫瘤,且大部分具有較快的生長速度和轉移能力。而本研究發現,相較於NF1-wild type MPNST細胞,ALA-PDT對NF1基因缺失的MPNST細胞具有更強的毒殺效果;並發現其原因為在NF1基因缺失的MPNST細胞內,由ALA轉換成之光感物質PpIX累積量相對較高的緣故。另外,本實驗室先前研究利用微脂體將化療藥物及光感物質包覆其內,以此種結合光動力治療與化學治療效應之腫瘤治療模式可以更加提升對癌症治療之效益。為了在將來能更進一步將光動力療法應用於臨床治療MPNST;本研究進行活體動物實驗 (in vivo study)發現施打雙效微脂體並進行光照處理的小鼠之腫瘤細胞生長將受到抑制、甚至消失,顯示光動力療法的確具有治療MPNST的潛力,並且可於將來應用於臨床治療。 | zh_TW |
dc.description.abstract | Malignant peripheral nerve sheath tumor (MPNST) is a kind of soft tissue sarcomas derived from peripheral nerves and has poor prognosis. MPNSTs appear in varied sizes and tend to metastasize to other parts of the body. In addition to the physical conditions, marked cosmetic disfigurements also cause psychological traumas. Because the tumors are resistant to chemical and radical treatments, no effective therapies are available except for surgical resection. 5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT), which involved the photochemical reactions based on the interaction of photosensitizing agents and light energy, has become a modality in anti-tumor therapy. Since the selective accumulation of ALA-derived protoporpyrin IX (PpIX) in tumor cells, topical illumination can specifically induce oxidative stress followed by cell death to tumors. In this study, significant cytotoxicity and reduced migration ability were found in MPNST cells after ALA-PDT. Besides, we found out that NF1-mutation MPNST cells, are more sensitive to PDT compared to NF1 wild type MPNST cells. We also treated MPNST cells with dual-effect liposome and find good therapeutic effects in vitro and in vivo. Our studies suggest that ALA-PDT and dual-effect liposome have potential therapeutic effects for the treatment of MPNST. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:02:09Z (GMT). No. of bitstreams: 1 ntu-101-R99b22013-1.pdf: 3817889 bytes, checksum: 89b161bfbd790cae3bbbb98374c8c6a8 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 中文摘要…………………………………………………………………………………………………………………….ii
英文摘要……………………………………………………………………………………………………………………iii 謝誌…………………………………………………………………………………………………………………………..iv 目錄……………………………………………………………………………………………………………………………vi 表目錄 …………………………………………………………………………………………………………………......x 圖目錄……………………………………………………………………………………………………………………… xi 縮寫表………………………………………………………………………………………………………………………xiii 第一章 緒論……………………………………………………………………………………………………………….1 1.0楔子 – 研究源起………………………………………………………………………………………….1 1.1第一型神經纖維瘤病 (Neurofibromatosis type 1, NF1)……………………...1 1.1.1 NF1的遺傳學 (genetics) 與生理病理學 (pathophysiology)……………1 1.1.2 NF1 基因的突變………………………………………………………….2 1.1.3 Neurofibromin蛋白質……………………………………………………..2 1.1.4 NF1之診斷準則與臨床病徵……………………………………………...3 1.1.4.1 NF1之診斷準則………………………………………………………3 1.1.4.2 NF1之臨床病徵………………………………………………………4 1.1.4.2.1 與NF1診斷準則相關的NF1臨床病徵………………………...4 1.1.4.2.2 其他和腫瘤相關的NF1臨床病徵……………………………...5 1.1.4.2.3 非腫瘤的NF1臨床病徵………………………………………...6 1.2 惡性周邊神經鞘瘤 (Malignant Peripheral Nerve Sheath Tumor)…………...6 1.3 光動力治療 (Photodynamic therapy, PDT)…………………………………..7 1.3.1 發展起源………………………………………………………………….8 1.3.2 作用原理與機制………………………………………………………...10 1.3.3 光感物質………………………………………………………………...11 1.3.3.1 五氨基酮戊酸 (5-Aminolevulinic acid, ALA)…………………….13 1.3.3.1.1 原血紅素生合成路徑 (Heme biosynthetic pathway)…………14 1.3.3.1.2 ALA之臨床應用優勢………………………………………….15 1.3.3.1.3 ALA-PDT之改良與發展………………………………………16 1.3.3.2 chlorin e6…….....................................................................................18 1.4 微脂體作為藥物載體的應用………………………………………………..18 1.4.1 微脂體簡介……………………………………………………………...18 1.4.1.1 起源…………………………………………………………………18 1.4.1.2 微脂體的組織結構…………………………………………………19 1.4.2 微脂體在藥物傳輸上的應用…………………………………………...20 1.4.3 微脂體應用於Doxorubicin藥物的包覆……………………………….20 1.4.3.1 Doxorubicin………………………………………………………….20 1.4.3.2 Liposomal-Doxorubicin……………………………………………...22 1.5研究動機與目的……………………………………………………………..22 第二章 材料與方法…………………………………………………………………..24 2.1 藥品與儀器………………………………………………………………….24 2.1.1 藥品……………………………………………………………………..24 2.1.2 細胞培養耗材…………………………………………………………..25 2.1.3 儀器……………………………………………………………………..26 2.2 細胞株………………………………………………………………………………………………………..28 2.3 細胞培養與繼代 (Subculture)……………………………………………………………………28 2.4 細胞解凍與冷凍 (Cell thawing and cryopreservation)……………………………….29 2.5 細胞計數 (Cell counting)……………………………………………………29 2.6 光動力治療…………………………………………………………………..30 2.6.1光動力處理………………………………………………………………30 2.6.2 細胞型態觀察………………………………….......................................31 2.7 細胞存活率檢測:粒腺體去氫酶活性分析 (MTT assay)…………………31 2.8 PpIX含量試驗 (PpIX accumulation assay)………………………………….32 2.8.1 收取細胞懸浮液 (Cell suspension acquisition)………………………...32 2.8.2 流式細胞儀分析螢光強度……………………………………………...32 2.8.3 細胞內PpIX含量計算 (Calculation of intracellular accumulation level of PpIX)…………………………………………………………………….32 2.9 細胞移動能力測試試驗 (Migration assay)………………………………………………..32 2.10 特定基因EGFR之定量分析………………………………………………33 2.10.1 RNA抽取前細胞進行ALA-PDT處理………………………………..33 2.10.2 RNA之抽取…………………………………………………………….33 2.10.3 反轉錄聚合酶鏈鎖反應 (Reverse Transcriptase Polymerase Chain Reaction, RT-PCR)……………………………………………………...33 2.10.4 PCR產物進行膠體電泳之分析………………………………………..34 2.11 微脂體製備……………………………………………………………………………………………….34 2.12 活體動物實驗……………………………………………………………………………………………35 2.12.1 動物與腫瘤模式…………………………………………………………………………………35 2.12.2 In vivo光動力治療……………………………………………………………………………..35 第三章 結果 ………………………………………………………………………….36 3.1 ALA-PDT對MPNST細胞株的毒殺效果以及存活下來的細胞狀況……..36 3.1.1 使用ALA-PDT處理三株MPNST細胞,STS26T、S462-TY、ST8814 3.1.1.1 ALA-PDT對MPNST細胞之毒殺效果……………………………36 3.1.1.2 不同株MPNST細胞之PpIX累積量有所差異…………………..37 3.1.2 MPNST細胞經過ALA-PDT處理後移動能力降低……………………37 3.1.3 特定基因EGFR之定量分析……………………………………………38 3.2雙效型微脂體應用於MPNST治療之細胞實驗與動物模式實驗………….38 3.2.1 雙效型微脂體應用於MPNST治療之in vitro細胞實驗………………39 3.2.1.1 抗癌藥物Doxorubicin對MPNST細胞之毒殺效果………………39 3.2.1.2 雙效型微脂體對MPNST細胞之毒殺效果………………………..39 3.2.2雙效型微脂體應用於MPNST治療之in vivo動物實驗……………….41 3.2.2.1 實驗裸鼠對於光動力治療後之癒後情形…………………………41 3.2.2.2 雙效型微脂體應用於活腫瘤之治療效果…………………………42 第四章 討論…………………………………………………………………………...43 4.1 ALA-PDT對MPNST細胞株的毒殺效果以及存活下來的細胞狀況……..43 4.1.1 ALA-PDT對於MPNST細胞株有顯著毒殺效果………………………43 4.1.2 經過ALA-PDT處理的細胞移動能力降低……………………………44 4.1.3 經過ALA-PDT處理的細胞中EGFR之mRNA 表現量降低……….44 4.2 雙效型微脂體應用於治療MPNST…………………………………………45 4.2.1 應用雙效型微脂體於MPNST之in vitro細胞實驗…………………..46 4.2.2 應用雙效型微脂體於MPNST之in vivo動物實驗…………………..48 第五章 結論 …………………………………………………………………………50 5.1 五氨基酮戊酸光動力治療 (ALA-PDT) 應用於惡性神經纖維鞘瘤 (MPNST) 之探討……………………………………………………………50 5.2 雙效型微脂體Lipo-Dox-Ce6應用於MPNST之細胞實驗與活體癌症治療…………………………………………………………………………….50 參考文獻………………………………………………………………………………84 | |
dc.language.iso | zh-TW | |
dc.title | 惡性神經纖維鞘瘤之光動力治療效果 | zh_TW |
dc.title | Effects of photodynamic therapy on Malignant Peripheral Nerve Sheath Tumor | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡翠敏(Tsui-Min Tsai),黃慶燦(Ching-Tsan Huang),李銘仁(Ming-Jen Lee) | |
dc.subject.keyword | 惡性神經纖維鞘瘤,五氨基酮戊酸光動力療法,雙效微脂體, | zh_TW |
dc.subject.keyword | malignant peripheral nerve sheath tumor,5-Aminolevulinic acid-mediated photodynamic therapy,dual-effect liposome, | en |
dc.relation.page | 93 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-08-03 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。